The company more than doubled its cash balance from the end of June with two fundraising transactions.
News & Analysis: PTC Therapeutics
The business is raising cash through two offerings: one of debt and one of common stock.
PTCT earnings call for the period ending June 30, 2019.
PTCT earnings call for the period ending December 31, 2018.
Earnings and some capital moves hurt these stocks.
The company announced the pricing of a share offering announced the day before.
The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.
The company's making an acquisition to bulk up its pipeline of clinical-stage drugs.
A new drug could move the needle someday, but competitive risks loom.
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.